用于质谱分析的最佳切割温度化合物中嵌入的人组织制备

Executive Industry Relevance

Enabling mass spectrometry analysis of sphingolipids from OCT-embedded human tissues unlocks retrospective access to large, well-annotated biorepository samples, overcoming a major barrier in translational lipidomics. This workflow expands the discovery pipeline by supporting robust, quantitative lipid profiling in disease-relevant human specimens, increasing predictive confidence for target validation and biomarker research. The protocol's compatibility with long-term archived tissues enhances portfolio flexibility and risk-adjusted decision-making in early discovery and translational studies.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of sphingolipid pathway alterations in human disease tissues.
• Supports functional target validation by quantifying lipid species in clinically annotated samples.
• Facilitates mechanistic de-risking by leveraging retrospective cohorts with rich clinicopathological data.

Screening & Assay Development

• Prepares high-quality, reproducible tissue extracts for downstream LC-ESI-MS/MS workflows.
• Standardizes sample normalization and internal standardization for quantitative lipidomics assays.
• Enables scalable screening of archived specimens for biomarker or target discovery.

Translational & Preclinical Research

• Aligns lipidomic outputs with disease phenotypes and clinical variables from biorepository metadata.
• Supports continuity from discovery through preclinical validation using human-relevant samples.
• Reduces translational risk by enabling direct comparison of tumor and matched normal tissues.

Pipeline & Workflow Integration

This protocol bridges early discovery and translational research by enabling robust lipidomic analysis of archived human tissues, supporting workflows from hypothesis testing to biomarker validation.

• Discovery Biology: Facilitates hypothesis-driven interrogation of sphingolipid metabolism in disease contexts.
• Screening: Provides reproducible, quantitative outputs for comparative lipidomics across large sample sets.
• Analytics: Delivers normalized, statistically analyzable data for cross-condition comparisons and cohort studies.
• Translational Research: Integrates with clinical annotation for biomarker alignment and disease mechanism studies.
• Enterprise Reuse: Establishes a reusable workflow for leveraging biorepository assets across multiple programs.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in lipid target validation and mechanistic studies.
• Operational Value: Standardizes sample preparation and data normalization for reproducibility and scalability.
• Strategic Value: Enables risk-adjusted advancement and capital-efficient use of archived clinical samples.
• Portfolio Impact: Expands accessible sample pools for prioritization and cross-program analyses.

Implementation Considerations

• Requires expertise in tissue handling, lipid extraction, and mass spectrometry analytics.
• Demands access to LC-ESI-MS/MS instrumentation and validated internal standards.
• Necessitates rigorous cross-team standardization for sample processing and data normalization.
• Adaptable to various tissue types but may require validation for non-sphingolipid classes.
• Dependent on quality and annotation of biorepository specimens for maximal translational value.

Biopharma FAQs